NRx subsidiary HOPE Therapeutics begins patient treatments using Zeta Surgical TMS navigation system

NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc.

NRXP

0.00
  • NRX Pharmaceuticals subsidiary HOPE Therapeutics began treating patients using Zeta Surgical’s FDA-cleared Zeta TMS Navigation System at two Florida clinics.
  • Rollout moves HOPE’s interventional psychiatry platform into routine, precision-guided outpatient TMS care for major depressive disorder.
  • Deployment supports NRX’s planned SPARC-TMS trial pairing NRX-101 with robotic-enabled TMS across civilian and military treatment sites.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606250700PRIMZONEFULLFEED9752538) on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.